American Century Companies Inc. Purchases 58,144 Shares of Aurinia Pharmaceuticals Inc $AUPH

Key Points

• American Century Companies Inc. increased its stake in Aurinia Pharmaceuticals by 33.9%, acquiring an additional 58,144 shares, bringing its total ownership to 229,734 shares valued at approximately $1.85 million.
• Wall Street analysts have a consensus Buy rating for Aurinia Pharmaceuticals, with price targets ranging from $9.00 to $17.00, showcasing optimism about the company's growth potential.
• Insider trading activity includes Director Kevin Tang purchasing 200,000 shares at an average price of $11.68, reflecting increased confidence in the company's future performance.

American Century Companies Inc. raised its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 33.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 229,734 shares of the biotechnology company's stock after acquiring an additional 58,144 shares during the period. American Century Companies Inc. owned approximately 0.17% of Aurinia Pharmaceuticals worth $1,847,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $27,000. Tower Research Capital LLC TRC boosted its holdings in Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $31,000. GAMMA Investing LLC boosted its holdings in Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after acquiring an additional 1,744 shares during the period. Finally, USA Financial Formulas bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $50,000. 36.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on AUPH shares. HC Wainwright restated a "buy" rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Royal Bank Of Canada raised their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $12.00.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 1,000,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, August 1st. The stock was bought at an average cost of $10.12 per share, with a total value of $10,120,000.00. Following the acquisition, the director owned 11,029,500 shares of the company's stock, valued at approximately $111,618,540. The trade was a 9.97% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have bought 1,300,000 shares of company stock worth $13,590,000. 12.20% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH traded down $0.13 during midday trading on Friday, reaching $12.40. 1,825,129 shares of the company's stock were exchanged, compared to its average volume of 1,785,721. The company's 50 day simple moving average is $10.28 and its two-hundred day simple moving average is $8.82. The firm has a market capitalization of $1.63 billion, a PE ratio of 28.84 and a beta of 1.26. Aurinia Pharmaceuticals Inc has a 12 month low of $6.42 and a 12 month high of $12.82. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.